MP-19.13: A multicenter, randomized, phase III trial of a novel autologous therapeutic vaccine (vitespen) vs. observation as adjuvant therapy in patients at high risk of recurrence after nephrectomy for renal cell carcinoma

✍ Scribed by C. Wood; B. Escudier; L. Lacombe; A. Hoos; R. Gupta; R. Flanigan; R. Figlin; P. Srivastava

• Book ID: 116946707
• Publisher: Elsevier Science
• Year: 2006
• Tongue: English
• Weight: 68 KB
• Volume: 68
• Category: Article
• ISSN: 0090-4295
• DOI: 10.1016/j.urology.2006.08.573